Hypertrophic Cardiomyopathy (HCM)
31
10
13
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
3.2%
1 terminated out of 31 trials
80.0%
-6.5% vs benchmark
6%
2 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (31)
COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Multicentre Hypertrophic Cardiomyopathy Registry
Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy
Perfusion Abnormalities in Hypertrophic Cardiomyopathy
HCMR Re-Imaging Study
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access
Mechanisms of Atrial Pathoelectrophysiology in HCM
Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)
Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy
One-stop Evaluation of Hypertrophic Cardiomyopathy in Cardiac Magnetic Resonance
Multimodal Analysis of Endomyocardial Biopsies
The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
The Application of T1 Mapping in Real-World
Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
Myocardial Energetic Restoration in the Treatment of Obstructive Hypertrophic Cardiomyopathy
ReGistry of hypeRtrophic cArDIomyopathy: Regional fEatures, geNeTics and Course
AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.